共 50 条
- [21] Failure of ipriflavone to significantly reduce vertebral fracture rates and to increase bone mineral density in postmenopausal osteoporosis: The IMEFS study.ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S383 - S383Reginster, JYAlexanderson, PDevogelaer, JPRoux, CGennari, CFechtenbaum, JToussaint, AChristiansen, C
- [22] Oral ibandronate reduces non-vertebral fracture risk in postmenopausal osteoporosis: Results from a sub-analysis of a pivotal studyBONE, 2008, 42 : S86 - S86Stakkestad, Jacob A.Emkey, RonaldNeate, ColinChesnut, Charles H.
- [23] Change in bone mineral density is predictive for fracture risk reduction with ibandronate: Further insights from a phase III study of intravenous ibandronate injection.JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S310 - S310Miller, PDEpstein, SHuss, HWilson, KMSchimmer, RCWasnich, R
- [24] Similar reductions in bone turnover markers with oral ibandronate and intravenous (IV) zoledronic acid for bone metastases from breast cancer:: Phase III trial results.JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S118 - S118Body, JLichinitser, MTjulandin, SGarnero, PBergström, B
- [25] Oral monthly ibandronate decreases bone turnover in postmenopausal women with low bone mass: Results from the monthly oral pilot study (MOPS)OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S5 - S5Reginster, JYWiese, CWilson, KSchimmer, RC
- [26] Fracture Risk with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Primary and Sensitivity Analyses from the eValuation of IBandronate Efficacy (VIBE) Database Fracture Study.JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S346 - S346Harris, S. T.Blumentals, W. A.Poston, S. A.Silverman, S. L.
- [27] Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonateOSTEOPOROSIS INTERNATIONAL, 2014, 25 (07) : 1953 - 1961Brown, J. P.Roux, C.Ho, P. R.Bolognese, M. A.Hall, J.Bone, H. G.Bonnick, S.van den Bergh, J. P.Ferreira, I.Dakin, P.Wagman, R. B.Recknor, C.
- [28] Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonateOsteoporosis International, 2014, 25 : 1953 - 1961J. P. BrownC. RouxP. R. HoM. A. BologneseJ. HallH. G. BoneS. BonnickJ. P. van den BerghI. FerreiraP. DakinR. B. WagmanC. Recknor
- [29] Safety of an intravenous (i.v.) dose of ibandronate followed by daily oral dosing in metastatic bone disease:: Results of an open-label study.JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 60S - 60SBody, JJLichinitser, MAndreeva, NBudde, MBergström, B
- [30] Fracture Risk in Women Aged 65 Years or Older with Once-Monthly Oral Ibandronate Compared with Weekly Bisphosphonates: Analyses From the eValuation of IBandronate Efficacy (VIBE) Database Fracture Study.JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S465 - S465Silverman, S. L.Blumentals, W. A.Poston, S. A.Harris, S. T.